AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02570256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deficit-fields to reduce error
Description: Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
Study NCT02570256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deficit-fields to expand range of motion
Description: Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
Study NCT02570256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deficit-fields to improve function
Description: Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
Study NCT00468065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer
Description: Veinveiwer is used to view veins subQ
Study NCT00468065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinviewer
Description: near infrared light reveals veins subcutaneously
Study NCT02053740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add R-S-Y-R-T (500 mg 3 times per day) for 6 months
Study NCT02053740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine western medicine
Study NCT02053740 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Routine western medicine
Study NCT00592735 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic gastric banding
Description: standard surgical procedure
Study NCT00496834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study NCT00496834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: carvedilol
Description: Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study NCT00496834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: losartan (+) hydrochlorothiazide (HCTZ)
Description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study NCT00496834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: carvedilol (+) hydrochlorothiazide
Description: Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study NCT03134261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WB-MRI
Description: scanning methods
Study NCT01777295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01777295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT00600405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Tamsulosin 0.4 mg orally daily for ten days.
Study NCT00600405 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard therapy with ibuprofen and oxycodone.
Description: Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
Study NCT03134261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SPECT-CT
Description: scanning methods
Study NCT03134261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cholin-PET-CT
Description: scanning methods
Study NCT03134261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA-PET-CT
Study NCT02900313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiac surgery
Description: Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
Study NCT03115229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Nursing Interventions for Reduction Obesity Risk
Description: Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks.
Study NCT00778518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARX201
Description: Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
Study NCT00778518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARX201
Description: Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
Study NCT00778518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARX201
Description: Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 200 mg oral capsule once daily
Study NCT02999724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300-600 mg 1 hour preop
Study NCT02999724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule(s) 1 hour preop
Study NCT01733043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT01733043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02381769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean based lipid emulsion
Study NCT04940416 — intervention group
Intervention type: DEVICE
Intervention: Neurofit (oculometric testing)
Description: The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
Study NCT02018354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Extra-Articular Tenodesis (LET)
Description: Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
Study NCT02018354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
Study NCT02018354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
Study NCT03005613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischial spine fascia fixation
Description: The participants will receive ischial spine fascia fixation.
Study NCT03005613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrospinous ligament fixation
Description: The participants will receive sacrospinous ligament fixation.
Study NCT02795520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167IV
Study NCT02624388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Estrogen-like compound (isoflavone) derived from soybeans
Study NCT02624388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill that contains no medicine
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 400 mg oral capsule once daily
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 800 mg oral capsule once daily
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder in capsule once daily
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection
Study NCT01925235 — intervention group
Intervention type: PROCEDURE
Intervention: remote ischemic preconditioning
Study NCT03994744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous administration of Sintilimab (1200mg/3weeks)
Study NCT03994744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
Study NCT02707588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
Study NCT02707588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
Study NCT02707588 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
Study NCT02707588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
Study NCT02635542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
Study NCT04854850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo
Description: The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle \& Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
Study NCT02635542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
Study NCT02660879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written Document Educational Resource
Description: A 2 page document with pictures discussing how to use an inhaler properly.
Study NCT02660879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Video Education
Description: Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
Study NCT02394236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
Study NCT03724266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: chitosan will be used as intracanal medication
Study NCT03724266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: intracanal medication
Study NCT01980810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bounded paclitaxel
Description: 200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
Study NCT01980810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
Study NCT01180790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
Study NCT02450552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine
Description: Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
Study NCT02450552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00937248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prone pillow and simple ankle fixation device
Description: Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
Study NCT00937248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Vacuum Immobilization Device (CVID)
Description: This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
Study NCT05020405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and ARS with GBR and SMV
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with SMV
Study NCT05020405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement and ARS with GBR
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
Study NCT01267084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
Study NCT01267084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
Study NCT01267084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or equivalent steroid
Description: Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
Study NCT01931241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHRO-001
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
Study NCT00347594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Generation Diagnostic Instrument (NGDI)
Description: Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
Study NCT00347594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zyoptix Diagnostic Workstation (ZDW)
Description: Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
Study NCT02769039 — intervention group
Intervention type: OTHER
Intervention: No intervention. Observational studies of sleep, movement and brain imaging
Description: Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
Study NCT00634049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
Study NCT01232621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Introduction of research personnel
Description: Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.